Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myelodysplastic Syndromes 19Leukemia, Myeloid, Acute 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia 8Hematologic Neoplasms 6Anemia, Refractory, with Excess of Blasts 6Lymphoma 5Primary Myelofibrosis 4Neoplasms 4Multiple Myeloma 4Mastocytosis 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Biphenotypic, Acute 4Graft vs Host Disease 4Lymphoma, Non-Hodgkin 3Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Myeloproliferative Disorders 2Melanoma 2Mastocytosis, Systemic 2Lymphohistiocytosis, Hemophagocytic 2Leukemia, Myelomonocytic, Acute 2Laryngeal Neoplasms 2Glioma 2

Interventions

Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Mast Cell Activation Disorders × Myeloid × Clear all
NCT01602939 2016-08-29

Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis

Hospital Virgen de la Salud

Phase 2/3 Unknown
10 enrolled
Myeloid

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡